Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price target of $8.00 for the company and are expecting that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cytori Therapeutics an industry rank of 92 out of 265 based on the ratings given to related companies.
CYTX has been the topic of a number of recent analyst reports. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 31st. Zacks Investment Research cut shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Finally, Roth Capital reiterated a “buy” rating and set a $11.00 price target on shares of Cytori Therapeutics in a report on Tuesday, June 28th.
An institutional investor recently bought a new position in Cytori Therapeutics stock. Cambridge Associates LLC MA ADV bought a new stake in Cytori Therapeutics Inc. (NASDAQ:CYTX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,000 shares of the company’s stock, valued at approximately $852,000. Cytori Therapeutics makes up about 0.4% of Cambridge Associates LLC MA ADV’s holdings, making the stock its 19th largest position. 18.48% of the stock is currently owned by institutional investors.
Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at 2.03 on Thursday. The company’s market cap is $41.60 million. Cytori Therapeutics has a one year low of $1.81 and a one year high of $6.45. The firm’s 50-day moving average is $2.09 and its 200-day moving average is $2.65.
Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.04. Cytori Therapeutics had a negative net margin of 203.79% and a negative return on equity of 210.47%. The firm had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $2.50 million. During the same quarter in the previous year, the company earned ($0.06) EPS. The company’s quarterly revenue was down 31.3% compared to the same quarter last year. On average, equities analysts anticipate that Cytori Therapeutics will post ($1.29) EPS for the current year.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.